Do you see patients with Myeloproliferative Neoplasms or Chronic Myelomonocytic Leukemia.
Learn about our research studies of an investigational agent targeting myelofibrosis and related diseases.
Patients who are diagnosed with myelofibrosis will experience constitutional symptoms, splenomegaly, an increased risk of transformation to acute myeloid leukemia (AML), and a shortened life expectancy. As an acquired clonal Philadelphia chromosome negative myeloproliferative neoplasm (MPN), myelofibrosis can present in a number of ways. Patients may be diagnosed with primary myelofibrosis or secondary myelofibrosis following progression of polycythemia vera (PV) to post-PV myelofibrosis, or essential thrombocythemia (ET) to post-ET myelofibrosis. Other than hematopoietic stem cell transplantation (HSCT), current therapies are unable to control all of the clinical manifestations of myelofibrosis. Our research is focusing on potential new treatment options, including combination strategies with ruxolitinib as the backbone treatment.
We are conducting several research studies to evaluate an investigational agent called navitoclax in patients with myelofibrosis and related diseases (polycythemia vera (PV), essential thrombocythemia (ET) and chronic myelomonocytic leukemia). The primary objective of this program is to evaluate the effect of navitoclax (in most cases, in combination with ruxolitinib) on reducing spleen volume in patients with myelofibrosis. We are also conducting a research study evaluating navitoclax monotherapy in patients across MPN disease types (including myelofibrosis, PV, and ET) and CMML. Patients in all of these studies may continue on the study treatment as long as they are receiving benefit. We need help from the local medical community to help us identify qualified study participants around the world.
Navitoclax is under clinical development and is not approved by regulatory health authorities. Safety and efficacy are under evaluation.